Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +10.00p +5.41% 195.00p 190.00p 200.00p 195.00p 185.00p 185.00p 95,226 16:18:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.3 -25.7 -35.0 - 120.76

Summit Corp Share Discussion Threads

Showing 38851 to 38873 of 38875 messages
Chat Pages: 1555  1554  1553  1552  1551  1550  1549  1548  1547  1546  1545  1544  Older
DateSubjectAuthorDiscuss
21/9/2017
16:14
Theres been a lot of Canaccord Genuity holding RNSs popping up on all sorts of stocks recently. I believe the reason is because Canaccord have recently bought out Hargreave Hale. So just re-stating existing holdings.
someuwin
21/9/2017
16:07
Hi football - This RNS is significant as it (I believe) is a new investor following recent share issues.
chrisatrdg
21/9/2017
16:02
Got another holding RNS today, they seem to be like buses none for ages then to come along at once https://uk.advfn.com/stock-market/london/summit-corp-SUMM/share-news/Summit-Therapeutics-plc-Summit-Therapeutics-Plc/75699207
football
21/9/2017
15:58
WORLD MUSCLE SOCIETY CONGRESS 3-7 October 2017, St Malo, France Posters of interest involving K.Davies & Summit staff Wednesday 4 October 2017 P.235 Circulating miRs biomarkers for therapeutic monitoring in utrophin based DMD therapy N. Ramadan; S. Guiraud; B. Edwards; S. Squire; S. Hemming; K. Davies P.239 Identification of serum protein biomarkers for utrophin based DMD therapy S. Guiraud; B. Edwards; S. Squire; A. Babbs; N. Shah; A. Berg; H. Chen; K. Davies Thursday 5 October 2017 P.308 Discovery of small molecule utrophin modulators for the therapy of Duchenne muscular dystrophy G. Wynne; A. Vuorinen; E. Emer; D. Conole; M. Chatzopoulou; S. Davies; A. Russell; S. Guiraud; S. Squire; A. Berg; B. Edwards; S. Hemming; T. Kennedy; L. Moir; K. Davies; S. Harriman; J. Tinsley; F. Wilson P.308 PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromid F. Muntoni; K. Maresh; K. Davies; S. Harriman; G. Layton; R. Rosskamp; A. Russell; B. Tejura; J. Tinsley P.469 Collection of high quality muscle biopsies for use in DMD clinical trial analysis; process development and implementation J. Tinsley; D. Frank; J. Dworzak; C. Faelan; J. Patterson-Kane; H. Wolff; F. Muntoni; PhaseOut DMD Study Group hTTp://www.wms2017.com/wp-content/uploads/2017/NMD%203415%20full%20prog_29Aug.pdf
chrisatrdg
21/9/2017
11:08
With funding out the picture for now i think it's a case of place your bets take a position and wait. Any over hang of shares should quickly clear imo
waterloo01
20/9/2017
21:45
I hope you are right football thanks for the posting.
chrisatrdg
20/9/2017
21:19
penny dropped at last? 12.69 up (3.68%)
football
20/9/2017
17:09
Is it just me ... or am I the only one who didn't get an email note about the RNS explaining Lansdowne have increased their holding?
hugus maximus
20/9/2017
16:39
Update on Summit Conferences WORLD MUSCLE SOCIETY CONGRESS 3-7 October 2017, St Malo, France ID WEEK 4-8 October 2017, San Diego, US
chrisatrdg
20/9/2017
14:40
Governments need to step in and encourage them - as Jim Neill (?) said a while back.
luminoso
20/9/2017
14:25
Interesting article Chris ... yet the major pharmas seem to have no interest, as they see little profit in anti-biotics and of course that's all they are motivated by ... what a sad and bizarre world.
hugus maximus
20/9/2017
13:50
Too few antibiotics in pipeline to tackle global drug-resistance crisis, WHO warns Article includes: 'Hospital infections such as C. difficile and MRSA (methicillin-resistant Staphylococcus aureus) are also of major concern. They are a particular danger to patients who are already sick and have fragile immune systems.' Link: hTTps://www.theguardian.com/society/2017/sep/19/too-few-antibiotics-in-pipeline-to-tackle-global-drug-resistance-crisis-who-warns?CMP=share_btn_tw
chrisatrdg
20/9/2017
12:50
Recent strengthening of pound/dollar might explain some price slippage.
luminoso
18/9/2017
15:55
Agree, waterloo.
luminoso
18/9/2017
14:05
I hope that one of the messages in the size if the raise at around 10% dilution, is that at least for the period leading up to the next major milestone (EZT), they don't need to raise again. If they didn't expect to see an upward movement in the market cap after that, they would probably have raised more now?
waterloo01
18/9/2017
13:18
The chart is still showing a nice uptrend despite the placing.
phowdo
18/9/2017
12:16
Cheers. Getting over the placing and nice to see a 31k share buy just printed.
waterloo01
18/9/2017
11:44
Nice one, waterloo.
luminoso
18/9/2017
08:53
Daily mail from Friday Eve htTp://www.dailymail.co.uk/money/investing/article-4888186/Summit-Therapeutics-sees-share-price-rise-15.html
waterloo01
17/9/2017
12:18
Thanks chrisatrdg. " Drug developer Summit Therapeutics PLC (LON:SMMT) will effectively secure its financial future with a fully underwritten issue of stock that could bring in as much as US$20mln." Which is why I do not have a problem with the price of the raising.
luminoso
16/9/2017
13:44
As others see us: Summit Therapeutics' US fundraiser should secure drug developer's long-term financial future 07:36 14 Sep 2017 Canaccord Genuity and JMP Securities are leading the American fundraiser, while Lansdowne Partners, one of Europe’s largest hedge funds, has come in as a cornerstone investor The company is getting some traction for its story Stateside Drug developer Summit Therapeutics PLC (LON:SMMT) will effectively secure its financial future with a fully underwritten issue of stock that could bring in as much as US$20mln. The AIM-listed firm, which is also quoted on the NASDAQ exchange, is issuing 1.459mln new American depositary shares at US$12 each, bringing in a minimum of US$17.5mln. A further 218,850 units are available to meet excess demand, which would take the total to US$20.1mln. Canaccord Genuity and JMP Securities are leading the American fundraiser, while Lansdowne Partners, one of Europe’s largest hedge funds, has come in as a cornerstone investor. US funding boost The injection of investor cash follows news last week Summit had secured a funding package of US$62mln from US authorities to bankroll the development of its next-generation antibiotic, Ridinilazole. READ: Summit Therapeutics soars after securing funding from US government agency Earlier this year it received a US$22mln milestone payment from the US biotech Sarepta related the progress of Ezutromid, its treatment for Duchenne Muscular Dystrophy (DMD), a rare muscle-wasting disease that affects boys. Ezutromid recently completed enrolment for its PhaseOut phase II clinical trial, which triggered the payment from partner Sarepta. Study underway The study recruited 40 patients in the US and UK and will take 48 weeks to complete. Researchers will assess how it affects muscle structure, health and function. Data from the half-way stage is expected in the first quarter of next year with the trial set to close in the third quarter. Blockbuster potential Ridinilazole, meanwhile, could be a blockbuster for the company as well as providing a breakthrough against antibiotic resistance. READ: Summit Therapeutics antibiotic delivers encouraging clinical trial results It is thought to be effective against multiple different strains of the difficult-to-treat infection c.difficile (CDI). It is also believed to be superior to existing medications such as vancomycin and metronidazole. “We believe ridinilazole can become a new, urgently needed frontline therapy for this serious infectious disease,” said chief executive Glyn Edwards said recently
chrisatrdg
15/9/2017
19:18
Additional shares have been taken out see press release below: hTTp://otp.investis.com/clients/uk/summit_corporation_plc/rns/regulatory-story.aspx?cid=1575&newsid=925782
chrisatrdg
15/9/2017
19:04
Thanks for the post waterloo01 I must say one of the more positive publication I have read on Summit for a while & concur with the sentiment of the article.Buy on the dip is a good way of looking at it.
chrisatrdg
Chat Pages: 1555  1554  1553  1552  1551  1550  1549  1548  1547  1546  1545  1544  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170922 04:26:06